PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC 50 s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model.
性状
Solid
IC50 & Target[1][2]
IC50: 2 nM (PERK), 9 nM (p-eIF2α)
体外研究(In Vitro)
PERK-IN-5 (compound 28) (10-48 μM) is relatively stable in both human and dog hepatocytes and is characterized with long half-lives. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
PERK-IN-5 (3-100 mg/kg; p.o.; 0.25-24 hours) has robust pharmacokinetics in CD1 mice, with C max of 3353 ng/mL, AUC 0-last of 5153 h*ng/mL, and bioavailability of 70%.
PERK-IN-5 (3 or 10 mg/kg; p.o.; twice daily, for 28 days) has statistically significant tumor growth inhibition. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Calvo V, et al. Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors. Bioorg Med Chem Lett. 2021;43:128058.
溶解度数据
In Vitro: DMSO : 250 mg/mL (533.62 mM; Need ultrasonic)配制储备液